XLV, the Health Care Select Sector SPDR ETF, enters the second half of May with a notable divergence: the ETF has stabilised near $145.85 after a rough month, yet short sellers have rebuilt positions at a pace that commands attention.
Short interest is the defining tension this week. Estimated short positions jumped 27% over five trading days to 3.76% of the float — a move from roughly 7.6 million shares on May 8 to nearly 9.8 million by May 12. To put that in context: shorts had been cutting exposure steadily through April, with SI sitting near 11–12 million shares in early April before falling to a month-low around 7.5 million by May 5. The reversal over the past week is sharp and concentrated, suggesting this is a deliberate tactical rebuild rather than passive drift. The ORTEX short score has climbed in lockstep, reaching 41.0 on May 12 from a low of 31.7 on May 4 — a meaningful step up, though still below the stressed levels seen in April.
Borrow conditions are tightening alongside positioning. Cost to borrow has more than doubled over the past month, reaching 0.48% — nearly double the sub-0.25% readings seen in late April. That remains inexpensive in absolute terms. Availability, however, has shifted more dramatically: the lending pool utilisation has gone from under 6% on May 4 to nearly 23% on May 12, the highest in roughly three weeks. The 52-week peak was 94.5%, so the borrow market is far from stressed, but the directional move is notable. There is still plenty of capacity for further short-building without triggering a squeeze dynamic.
Options positioning paints a persistently defensive backdrop — though it has actually eased slightly from extreme levels. The put/call ratio is running at 2.16, fractionally below its 20-day average of 2.20. That keeps it well inside normal range on a z-score basis (-0.26), but the absolute level tells a more meaningful story: XLV options buyers have maintained roughly two puts for every call for most of the past two months. The 52-week high was 2.67, hit in early April at the height of tariff anxiety, and the current reading is firmly in that elevated band. Healthcare-specific regulatory and policy risk — drug pricing reform, Medicaid budgets — has kept the defensive premium elevated well past the April volatility spike.
The macro backdrop provides context for the short rebuild. President-elect Warsh's Senate confirmation as Fed Chair today reinforces a rate environment that favours defensive sectors in theory, yet healthcare has lagged the broader tape. XLV is down almost 1% over the past month against a market that has recovered sharply. Key holdings like LLY remain the subject of active debate — today's news flow includes both a bullish analyst note on an obesity drug challenger following Eli Lilly's playbook, and an ABBV executive signalling openness to combining obesity assets — reflecting the ongoing repositioning within large-cap pharma that the ETF is absorbing. CVS also attracted a target raise from Bernstein to $106 today, a positive signal for the managed-care component. The near-term institutional flow picture is mixed: JPMorgan added over 2.9 million shares in the last reported period while Harel Insurance trimmed nearly 1.4 million — a split that mirrors the broader tactical uncertainty around the sector.
The next meaningful read will come from how short interest and borrow cost evolve against the ETF's price action: if XLV holds above $145 while shorts continue to rebuild, the gap between positioning and price direction widens into an increasingly testable setup.
See the live data behind this article on ORTEX.
Open XLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
